Sign In
Upcoming Event
Free Newsletter
Haystack Oncology using Johns Hopkins-developed research in breast cancer clinical study
Haystack Oncology has a 20,000-square-foot lab within the City Garage Science & Technology Center in south Baltimore at 101 West Dickman St. The 135,000-square-foot life sciences building is owned by South Duvall, which acquired the property in October 2021. (Loopnet photo)
Haystack Oncology using Johns Hopkins-developed research in breast cancer clinical study
Listen to this articleBiotech company Haystack Oncology, a Quest Diagnostics company with a clinical development lab in Baltimore, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology’s personalized MRD technology in a breast cancer clinical study.
The technology is the culmination of more than 20 years of technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine.
The clinical study will help evaluate therapeutic response and provide molecular insights for a Rutgers Cancer Institute clinical trial examining early-stage triple-negative breast cancer (TNBC) patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.
Rutgers Cancer Institute together with RWJBarnabas Health is the state’s only National Cancer Institute-designated comprehensive cancer center.
Haystack Oncology has a 20,000-square-foot lab within the City Garage Science & Technology Center in south Baltimore at 101 West Dickman St. The 135,000-square-foot life sciences building is owned by South Duvall, which acquired the property in October 2021. In addition to its lab in Baltimore, Haystack Oncology operates development labs in Hamburg, Germany and Helsinki, Finland.
